Serotonin 5-HT6receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease

Journal of Medicinal Chemistry

Volumn 57, Issue 17, 2014, Pages 7160-7181

  Benhamú, Bellinda ^a   Martín Fontecha, Mar ^a   Vázquez Villa, Henar ^a   Pardo, Leonardo ^b   López Rodríguez, María L ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLE DERIVATIVE; SEROTONIN 6 ANTAGONIST; SULFONAMIDE; SEROTONIN 6 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; LEARNING DISORDER; MEMORY DISORDER; NEUROTRANSMISSION; PHARMACOPHORE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; COGNITION DISORDERS; METABOLISM; PROTEIN TERTIARY STRUCTURE;

ALZHEIMER DISEASE; BINDING SITES; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 84920128903     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5003952     Document Type: Article

References (199)

1. Global Health and Aging (2011, publication by the National Institute on Aging and National Institutes of Health). http://www.who.int/ageing/publications/global-health.pdf (accessed May 14, 2014).
2. Alzheimer's Disease International: World Alzheimer Report 2013. http://www.alz.co.uk/research/WorldAlzheimerReport2013.pdf (accessed May 14, 2014).
3. Medicines in Development. Alzheimer's Disease (2013, report published by the Pharmaceutical Research and Manufacturers of America (PhRMA)). http://www.phrma.org/sites/default/files/Alzheimer%27s%202013.pdf (accessed May 14, 2014).
4. Querfurth, H. W.; LaFerla, F. M. Mechanisms of disease. Alzheimer's disease N. Engl. J. Med. 2010, 362, 329-344
5. LaFerla, F. M. Pathways linking A-beta and tau pathologies Biochem. Soc. Trans. 2010, 38, 993-995
6. Scarpini, E.; Scheltens, P.; Feldman, H. Treatment of Alzheimer's disease: current status and new perspectives Lancet Neurol. 2003, 2, 539-547
7. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimer's disease: clinical trials and drug development Lancet Neurol. 2010, 9, 702-716
8. Palmer, A. M. Neuroprotective therapeutics for Alzheimer's disease: progress and prospects Trends Pharmacol. Sci. 2011, 32, 141-147
9. Standridge, J. B. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease Clin. Ther. 2004, 26, 615-630
10. Thomas, S. J.; Grossberg, G. T. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias Clin. Interventions Aging 2009, 4, 367-377
11. 6receptor antagonists for the treatment of Alzheimer's disease Curr. Top. Med. Chem. 2008, 8, 1035-1048
12. Buckingham, S. D.; Jones, A. K.; Brown, L. A.; Sattelle, D. B. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection Pharmacol. Rev. 2009, 61, 39-61
13. Haydar, S. N.; Dunlop, J. Neuronal nicotinic acetylcholine receptors-targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease Curr. Top. Med. Chem. 2010, 10, 144-152
14. 7nicotinic acetylcholine receptor mechanisms in Alzheimer's disease Biochem. Pharmacol. 2011, 82, 931-942
15. Melancon, B. J.; Tarr, J. C.; Panarese, J. D.; Wood, M. R.; Lindsley, C. W. Allosteric modulation of the M-1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease Drug Discovery Today 2013, 18, 1185-1199
16. Carter, M. D.; Simms, G. A.; Weaver, D. F. The development of new therapeutics for Alzheimer's disease Clin. Pharmacol. Ther. 2010, 88, 475-486
17. Terry, A. V.; Callahan, P. M.; Hall, B.; Webster, S. J. Alzheimer's disease and age-related memory decline (preclinical) Pharmacol., Biochem. Behav. 2011, 99, 190-210
18. Mitchell, R. A.; Herrmann, N.; Lanctot, K. L. The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease CNS Neurosci. Ther. 2011, 17, 411-427
19. Yu, J. T.; Wang, N. D.; Ma, T.; Jiang, H.; Guan, J.; Tan, L. Roles of β-adrenergic receptors in Alzheimer's disease: implications for novel therapeutics Brain Res. Bull. 2011, 84, 111-117
20. Xu, Y. Q.; Yan, J. Q.; Zhou, P.; Li, J. J.; Gao, H. M.; Xia, Y.; Wang, Q. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease Prog. Neurobiol. 2012, 97, 1-13
21. Rodriguez, J. J.; Noristani, H. N.; Verkhratsky, A. The serotonergic system in ageing and Alzheimer's disease Prog. Neurobiol. 2012, 99, 15-41
22. Geldenhuys, W. J.; Van der Schyf, C. J. Role of serotonin in Alzheimer's disease: a new therapeutic target? CNS Drugs 2011, 25, 765-781
23. Nichols, D. E.; Nichols, C. D. Serotonin receptors Chem. Rev. 2008, 108, 1614-1641
24. 6receptors in learning and memory Trends Pharmacol. Sci. 2008, 29, 482-492
25. 6pharmacology inconsistencies Pharmacol., Biochem. Behav. 2011, 98, 169-172
26. Marazziti, D.; Baroni, S.; Borsini, F.; Picchetti, M.; Vatteroni, E.; Falaschi, V.; Catena-Dell'Osso, M. Serotonin receptors of type 6 (5-HT6): from neuroscience to clinical pharmacology Curr. Med. Chem. 2013, 20, 371-377
27. 6receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders Pharmacol. Ther. 2008, 117, 207-231
28. 6receptor in depression and anxiety: an overview of preclinical data Pharmacol. Rep. 2010, 62, 564-577
29. 6receptor ligands as potential cognitive enhancers and antiobesity agents Drug Discovery Today 2006, 11, 283-299
30. 6receptor antagonists: prospects for the treatment of cognitive disorders including dementia Curr. Opin. Drug Discovery Dev. 2008, 11, 642-654
31. 6receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease Neurotherapeutics 2008, 5, 458-469
32. 6receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease Exp. Rev. Neurother. 2009, 9, 1073-1085
33. 6antagonists as potential treatment for cognitive dysfunction Drug Dev. Res. 2009, 70, 145-168
34. 6antagonists Drugs Future 2009, 34, 969-975
35. 6receptor antagonists as potential therapeutics for cognitive impairment Curr. Top. Med. Chem. 2010, 10, 207-221
36. 6receptor memory and amnesia: behavioral pharmacology-learning and memory processes Int. Rev. Neurobiol. 2011, 96, 27-47
37. 6receptor and cognition Curr. Opin. Pharmacol. 2011, 11, 94-100
38. 6receptors and Alzheimer's disease Alzheimer's Res. Ther. 2013, 5, 15
39. Monsma, F. J., Jr; Shen, Y.; Ward, R. P.; Hamblin, M. W.; Sibley, D. R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs Mol. Pharmacol. 1993, 43, 320-327
40. 6) receptor-molecular-cloning, localization and stimulation of cAMP accumulation Biochem. Biophys. Res. Commun. 1993, 193, 268-276
41. 6serotonin receptor J. Neurochem. 1996, 66, 47-56
42. Venkatakrishnan, A. J.; Deupi, X.; Lebon, G.; Tate, C. G.; Schertler, G. F.; Babu, M. M. Molecular signatures of G-protein-coupled receptors Nature 2013, 494, 185-194
43. Wacker, D.; Wang, C.; Katritch, V.; Han, G. W.; Huang, X. P.; Vardy, E.; McCorvy, J. D.; Jiang, Y.; Chu, M.; Siu, F. Y.; Liu, W.; Xu, H. E.; Cherezov, V.; Roth, B. L.; Stevens, R. C. Structural features for functional selectivity at serotonin receptors Science 2013, 340, 615-619
44. 6receptor-like material in the rat central nervous system Brain Res. 1997, 746, 207-219
45. 6receptors Neuropsychopharmacology 1999, 21, S68-S76
46. Hirst, W. D.; Abrahamsen, B.; Blaney, F. E.; Calver, A. R.; Aloj, L.; Price, G. W.; Medhurst, A. D. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling Mol. Pharmacol. 2003, 64, 1295-1308
47. Setola, V.; Roth, B. L. Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants Mol. Pharmacol. 2003, 64, 1277-1278
48. 6receptor in the rat-brain-a study using antisense oligonucleotides J. Pharmacol. Exp. Ther. 1995, 274, 173-180
49. 6receptors in retention of spatial learning in the Morris water maze Neuropharmacology 2001, 41, 210-219
50. 6receptors Br. J. Pharmacol. 1998, 124, 556-562
51. Bromidge, S. M.; King, F. D.; Wyman, P. A. Preparation of N -(piperazinylphenyl)arylsulfonamides as CNS agents. PCT Int. Appl. WO9827081 A1, 1998.
52. 6receptor antagonist J. Med. Chem. 1999, 42, 202-205
53. 6receptor antagonist, Ro 04-6790 Psychopharmacology 2003, 170, 358-367
54. 6receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats Neuropsychopharmacology 2004, 29, 93-100
55. 6receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats Synapse 1996, 23, 164-173
56. 6receptor antagonist J. Med. Chem. 2003, 46, 1273-1276
57. 6receptor-mediated acetylcholine release Eur. J. Neurosci. 2006, 24, 1299-1306
58. 6receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus Neuropsychopharmacology 2001, 25, 662-668
59. 6receptor agonists: WAY-181187 and WAY-208466 Neuropsychopharmacology 2008, 33, 1323-1335
60. 6receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation-an effect sensitive to NMDA receptor antagonism Neuropharmacology 2004, 47, 195-204
61. 6receptors Curr. Drug Targets: CNS Neurol. Disord. 2004, 3, 59-79
62. 6receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus Neuroscience 2009, 164, 692-701
63. Myhrer, T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks Brain Res. Rev. 2003, 41, 268-287
64. 6receptors: relevance for cognitive effects Int. J. Neuropsychopharmacol. 2010, 13, 775-784
65. 6receptor mRNA expression during memory consolidation and amnesia Neurobiol. Learn. Mem. 2010, 93, 99-110
66. 6receptors in the rat dorsomedial striatum impairs instrumental learning Neuropsychopharmacology 2007, 32, 1520-1530
67. 6receptors in cognitive and non-cognitive symptoms in Alzheimer's disease Neuropsychopharmacology 2004, 29, 410-416
68. 6receptor polymorphism C267T in Alzheimer's disease Neurosci. Lett. 1999, 276, 138-139
69. 6receptor gene in Alzheimer's disease Neurosci. Lett. 2002, 325, 13-16
70. 6receptors: a novel target for cognitive enhancement Pharmacol. Ther. 2005, 108, 320-333
71. 6receptors positively coupled to adenylyl-cyclase in striatal neurons in culture NeuroReport 1994, 5, 2553-2557
72. 2+signaling using an enabling chimeric G-protein Eur. J. Pharmacol. 2003, 472, 33-38
73. 6receptor through an interaction with Fyn J. Biol. Chem. 2007, 282, 5496-5505
74. 7serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors Neuropsychopharmacology 2007, 32, 1840-1854
75. 6receptors in rat, pig and human brain tissue Br. J. Pharmacol. 2000, 130, 1597-1605
76. 6receptor in cognitive function Neuropharmacology 2008, 55, 1015-1022
77. Roth, B. L.; Craigo, S. C.; Choudhary, M. S.; Uluer, A.; Monsma, F. J., Jr.; Shen, Y.; Meltzer, H. Y.; Sibley, D. R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors J. Pharmacol. Exp. Ther. 1994, 268, 1403-1410
78. 6receptor Mol. Pharmacol. 1997, 52, 515-523
79. 6receptor antagonists for the treatment of CNS diseases Expert Opin. Ther. Pat. 2002, 12, 513-527
80. 6receptor Drugs Future 2005, 30, 479-495
81. Zimmer, L.; Le Bars, D. Current status of positron emission tomography radiotracers for serotonin receptors in humans J. Labelled Compd. Radiopharm. 2013, 56, 105-113
82. 6ligand C-11 GSK215083 determined from human whole-body PET Mol. Imaging Biol. 2012, 14, 517-521
83. 6receptor J. Med. Chem. 2010, 53, 7095-7106
84. 6serotonin receptors J. Med. Chem. 2000, 43, 1011-1018
85. 6antagonists Bioorg. Med. Chem. Lett. 2000, 10, 2295-2299
86. 6receptor ligands J. Med. Chem. 2001, 44, 3881-3895
87. 6Receptor Ligands with Therapeutic Potential. In Progress in Medicinal Chemistry, 1 st ed.; Lawton, G.; Witty, D. R., Eds.; Elsevier: Amsterdam, 2009; Vol. 48, pp 163-224.
88. 6receptor ligands with a focus on arylsulfonyltryptamine analogs Curr. Top. Med. Chem. 2010, 10, 579-595
89. 6medicinal chemistry Int. Rev. Neurobiol. 2010, 94, 1-34
90. 6receptor antagonists: a patent update. Part 1. Sulfonyl derivatives Expert Opin. Ther. Pat. 2012, 22, 917-964
91. 6R ligands: a comprehensive insight into their selectivity and activity Curr. Bioact. Compd. 2013, 9, 64-100
92. 6) receptor antagonists J. Med. Chem. 2005, 48, 4216-4219
93. 6serotonin receptors J. Med. Chem. 2006, 49, 5217-5225
94. 6ligands from common feature pharmacophore hypotheses J. Chem. Inf. Model. 2008, 48, 197-206
95. 6receptors Bioorg. Med. Chem. Lett. 2004, 14, 4569-4573
96. 6serotonin receptors: receptor modeling studies J. Med. Chem. 2008, 51, 603-611
97. 6receptor antagonists. Molecular mechanisms of receptor inactivation J. Med. Chem. 2010, 53, 1357-1369
98. 6receptor J. Neurochem. 1998, 71, 2169-2177
99. 6receptor antagonists Bioorg. Med. Chem. Lett. 2002, 12, 1357-1360
100. 6mediated disorders such as Alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and Parkinson's disease. PCT Int. Appl. WO2007004959 A1, 2007.
101. 6receptor antagonists J. Med. Chem. 2012, 55, 9255-9269
102. 6antagonists: identification of N -(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134) Bioorg. Med. Chem. Lett. 2001, 11, 55-58
103. 6receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models Eur. J. Pharmacol. 2006, 553, 109-119
104. 6receptor and their preparation and pharmaceutical compositions. PCT Int. Appl. WO2006126938 A1, 2006.
105. MacDonald, G. J.; Thompson, M. Preparation of novel phenyl sulfone derivatives and their use in the treatment of CNS disorders. PCT. Int. Appl. WO2004080986 A1, 2004.
106. 6R) antagonists with unique structural features J. Med. Chem. 2011, 54, 7030-7054
107. 6receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats Neurobiol. Learn. Mem. 2011, 96, 392-402
108. 6serotonin receptor binding affinities of N -1-benzenesulfonyl and related tryptamines Med. Chem. Res. 2000, 10, 230-242
109. 6receptors Bioorg. Med. Chem. Lett. 2006, 16, 5832-5835
110. 6ligands Bioorg. Med. Chem. Lett. 2008, 18, 3929-3931
111. 6antagonists. PCT Int. Appl. WO9947516 A1, 1999.
112. 6receptor inhibitors. U.S. Pat. Appl. US6133287A, 2000.
113. 6receptor antagonists Bioorg. Med. Chem. Lett. 2005, 15, 379-383
114. 6receptor ligands J. Med. Chem. 2005, 48, 1781-1795
115. 6receptor agonists and antagonists J. Med. Chem. 2005, 48, 353-356
116. 6receptor affinity. PCT Int. Appl. WO2002102774 A1, 2002.
117. Bromidge, S. M. Preparation of 4-piperazinoindoles for treating CNS disorders. PCT Int. Appl. WO2002041889 A2, 2002.
118. Caldirola, P.; Johansson, G.; Nilsson, B. M. 2-, 3-, 4-, or 5-Substituted-1-(benzenesulfonyl)indoles and their use in therapy. PCT Int. Appl. WO2002032863 A1, 2002.
119. 6receptor antagonists Bioorg. Med. Chem. Lett. 2005, 15, 4867-4871
120. 6receptor antagonist Ro 4368554 in rat models for cognition and sensorimotor gating Eur. Neuropsychopharmacol. 2007, 17, 277-288
121. 6receptor affinity. PCT Int. Appl. WO2002098857 A1, 2002.
122. 6modulators. PCT Int. Appl. WO2004026830 A1, 2004.
123. 6ligands. PCT Int. Appl. WO2004009548 A1, 2004.
124. 6antagonists, for treating CNS disorders. PCT Int. Appl. WO2004050085 A1, 2004.
125. 6receptor. PCT Int. Appl. WO2002060871 A2, 2002.
126. 6receptor ligands Bioorg. Med. Chem. Lett. 2012, 22, 7431-7435
127. 6antagonists Bioorg. Med. Chem. Lett. 2012, 22, 1494-1498
128. Johansson, G.; Jenmalm-Jensen, A.; Beierlein, K. Preparation of pyridino-fused heterocycles useful for the treatment of obesity, type II diabetes and CNS disorders. PCT Int. Appl. WO2004000828 A1, 2003.
129. 6receptor affinity. Eur. Pat. Appl. EP941994 A1, 1999.
130. Liu, K. G.; Robichaud, A. J.; Bernotas, R. C.; Yan, Y. F.; Lo, J. R.; Zhang, M. Y.; Hughes, Z. A.; Huselton, C.; Zhang, G. M.; Zhang, J. Y.; Kowal, D. M.; Smith, D. L.; Schechter, L. E.; Comery, T. A. 5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists J. Med. Chem. 2010, 53, 7639-7646
131. 6receptor modulators for treating CNS disorders. U.S. Pat. Appl. US20070037802 A1, 2007.
132. Haydar, S. N.; Andrae, P. M.; Yun, H.; Robichaud, A. J. 1-(Arylsulfonyl)-4-(piperazin-1-yl)-1 H -benzimidazole compounds as 5-hydroxytryptamine-6 receptor ligands and their preparation and use in the treatment of diseases. U.S. Pat. Appl. US20100120779 A1, 2010.
133. Cole, D. C. Preparation of N -sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands. PCT Int. Appl. WO2005012311 A1, 2005.
134. 6receptor J. Med. Chem. 2010, 53, 5186-5196
135. 6R) antagonists J. Med. Chem. 2011, 54, 8161-8173
136. 6receptors. Substituted 3-(phenylsulfonyl)pyrazolo[1,5- a ]pyrido[3,4- e ]pyrimidines and 3-(phenylsulfonyl)pyrazolo[1,5- a ]pyrido[4,3- d ]pyrimidines-synthesis and "structure-activity" relationship Bioorg. Med. Chem. Lett. 2012, 22, 4273-4280
137. 6receptor antagonists Eur. J. Med. Chem. 2011, 46, 1189-1197
138. 6receptor ligands. U.S. Pat. Appl. US20050020575 A1, 2005.
139. 6antagonists, for treating CNS disorders. PCT Int. Appl. WO2004078176 A1, 2004.
140. 6receptor antagonists Bioorg. Med. Chem. Lett. 2007, 17, 3504-3507
141. 6receptor inhibitors, and therapeutic uses. PCT Int. Appl. WO2006134150 A1, 2006.
142. 6ligands. PCT Int. Appl. WO2005037830 A1, 2005.
143. Krauss, N. E.; Zhao, S.-H. Preparation of chroman derivatives as 5-HT receptor ligands. PCT Int. Appl. WO2006066756 A1, 2006.
144. 2Areceptor or both. PCT Int. Appl. WO2005105776 A1, 2005.
145. 6receptor antagonist showing activity in rat social recognition test Bioorg. Med. Chem. Lett. 2012, 22, 1421-1426
146. 6serotonin receptor ligands Bioorg. Med. Chem. Lett. 2005, 15, 1707-1711
147. 2Areceptor antagonists for treatment of CNS disorders. PCT Int. Appl. WO2006066790 A1, 2006.
148. 6serotonin receptor antagonists J. Med. Chem. 2009, 52, 6153-6157
149. 6modulators. PCT Int. Appl. WO2006081332 A1, 2006.
150. 6serotonin receptor modulators. PCT Int. Appl. WO2001009142 A1, 2001.
151. Kelly, M. G.; Greenblatt, L. P.; Zhang, G.; Palmer, Y. L.; Lenicek, S. E. Preparation of 2-(aminoalkyl)chromans and benzofurans as 5-hydroxytryptamine-6 ligands for treatment of CNS disorders. PCT Int. Appl. WO2003029239 A1, 2003.
152. 6receptor antagonists. U.S. Pat. Appl. US20070027161 A1, 2007.
153. 6antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats Int. J. Neuropsychopharmacol. 2010, 13, 1021-1033
154. 6antagonists Bioorg. Med. Chem. Lett. 2009, 19, 2409-2412
155. 6modulators. PCT Int. Appl. WO2004080969 A1, 2004.
156. 6antagonists for treating central nervous system diseases and gastrointestinal tract disorders. U.S. Pat. Appl. US20040092512 A1, 2004.
157. 2Areceptor antagonists, their preparation, pharmaceutical compositions, and use in therapy. PCT Int. Appl. WO2006061126 A2, 2006.
158. 6receptor antagonists Bioorg. Med. Chem. Lett. 2008, 18, 738-743
159. Hostetler, G.; Dunn, D.; McKenna, B. A.; Kopec, K.; Chatterjee, S. Lactam and oxazolidinone derived potent 5-hydroxytryptamine 6 receptor antagonists Bioorg. Med. Chem. Lett. 2014, 24, 2094-2097
160. Cole, D. C.; Kelly, M. G.; Bravo, B. A.; Palmer, Y. L. Preparation of 1-(indol-3-yl)alkylidenehydrazine carboximidamides as 5-hydroxytryptamine-6 ligands. U.S. Pat. Appl. US20030232843 A1, 2003.
161. 6receptor inverse agonists Chem. Biol. Drug Des. 2014, 83, 666-669
162. Ivashchenko, A. A.; Ivashchenko, A. V.; Lavrovsky, Y. V.; Mitkin, O. D.; Savchuk, N. F.; Tkachenko, S. Y.; Okun, I. M. Preparation of 1,2,3,4-tetrahydro-1 H -pyrido[4,3- b ]indoles and 1,2,3,4,5,6-hexahydroazepino[4,3- b ]indoles as ligands for α-adrenoceptors and for dopamine, histamine, imidazoline and serotonin receptors and their use in treatment of CNS diseases. PCT Int. Appl. WO2009082268 A2, 2009.
163. 6antagonist with acute cognition enhancing activities Biochem. Pharmacol. 2009, 78, 1035-1042
164. Shahid, M.; Walker, G. B.; Zorn, S. H.; Wong, E. H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature J. Psychopharmacol. 2009, 23, 65-73
165. 6receptor antagonist Br. J. Pharmacol. 2000, 130, 1606-1612
166. 6receptor antagonists enhance retention of a water maze task in the rat Psychopharmacology 2001, 158, 114-119
167. 6receptor ligands and their biological functions Curr. Top. Med. Chem. 2002, 2, 643-654
168. 6) receptor antagonists in rodent models of learning J. Pharmacol. Exp. Ther. 2003, 307, 682-691
169. 6receptor antagonist Ro 04-6790 on learning consolidation Behav. Brain Res. 2001, 118, 107-110
170. 6receptor antagonists improve performance in an attentional set shifting task in rats Psychopharmacology 2005, 181, 253-259
171. 6receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task Pharmacol., Biochem. Behav. 2005, 81, 673-682
172. 6receptor antagonist, enhances novel object discrimination (NOD) memory J. Pharmacol. Sci. 2006, 101, 150
173. 6receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat Br. J. Pharmacol. 2008, 155, 434-440
174. Studies found in clinical trials for SB-742457: http://clinicaltrials.gov/ct2/results?term=SB-742457+&Search=Search (accessed May 14, 2014).
175. 6receptor antagonist, SB-742457, in Alzheimer's disease Curr. Alzheimer Res. 2010, 7, 374-385
176. Maher-Edwards, G.; Dixon, R.; Hunter, J.; Gold, M.; Hopton, G.; Jacobs, G.; Hunter, J.; Williams, P. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study Int. J. Geriatr. Psychiatry 2011, 26, 536-544
177. GlaxoSmithKline study AZ3110865 of compound SB-742457, September 21, 2011: http://www.gsk-clinicalstudyregister.com/study/AZ3110865#rs (accessed May 14, 2014).
178. GlaxoSmithKline study AZ3110866 of compound SB-742457, September 21, 2011: http://www.gsk-clinicalstudyregister.com/study/AZ3110866#rs (accessed May 14, 2014).
179. GlaxoSmithKline Product Development Pipeline 2013. February, 2013. http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK%202013%20Pipeline.pdf (accessed May 14, 2014).
180. Studies found in clinical trials for SAM-315: http://clinicaltrials.gov/ct2/results?term=sam-315&Search=Search (accessed May 14, 2014).
181. Studies found in clinical trials for SAM-531: http://clinicaltrials.gov/ct2/results?term=sam-531&Search=Search (accessed May 14, 2014).
182. Studies found in clinical trials for SRA-444: http://clinicaltrials.gov/ct2/results?term=sra-444&Search=Search (accessed May 14, 2014).
183. Studies found in clinical trials for dimebolin: http://clinicaltrials.gov/ct2/results?term=dimebolin&Search=Search (accessed May 14, 2014).
184. Doody, R. S.; Gavrilova, S. I.; Sano, M.; Thomas, R. G.; Aisen, P. S.; Bachurin, S. O.; Seely, L.; Hung, D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study Lancet 2008, 372, 207-215
185. Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon in Alzheimer's Disease. January 16, 2012. http://www.pfizer.com/news/press-release/press-release-archive-detail/medivation-and-pfizer-announce-results-from-phase-3-concert-trial-of-dimebon-in-alzheimer-s-disease (accessed May 14, 2014).
186. 6Drug Candidate. April 18, 2007. http://www.drugs.com/clinical-trials/epix-pharmaceuticals-announces-statistically-significant-results-cognitive-function-phase-1b-645.html (accessed May 14, 2014).
187. EPIX Pharmaceuticals Announces Discontinuation of PRX-00023 Clinical Development Program. March 20, 2008. http://www.reuters.com/article/2008/03/20/idUS99490+20-Mar-2008+BW20080320 (accessed May 14, 2014).
188. Roche Full Year 2005. Presentation to Analysts. February, 2006. http://www.roche.com/irp060201.pdf (accessed May 14, 2014).
189. SYN120 for the treatment of Alzheimer's disease and other cognitive disorders. http://www.biotie.com/en/investors/releases/release?NewsItemID=1478642&NewsItemYear=2011 (accessed May 14, 2014).
190. Studies found in clinical trials for ABT-354: http://clinicaltrials.gov/ct2/results?term=abt-354&Search=Search (accessed May 14, 2014).
191. Suven Presented Positive Phase-I Clinical Data of SUVN-502 for Alzheimer's Disease at ICAD 2009, Vienna, Austria. July 27, 2009. http://suven.com/news-July2009-27.htm (accessed May 14, 2014).
192. Suven's Alzheimer Drug Candidate SUVN-502 Successfully Completed All Chronic Toxicological (Tox) Studies and Demonstrated Very High Margin of Safety (MOS). May 18, 2011. http://www.suven.com/news-May2011-18.htm (accessed May 14, 2014).
193. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase II Clinical Studies. February 1, 2010. http://www.avineuro.com/avineuro-pharmaceuticals-inc-announces-beginning-of-phase-ii-clinical-studies-of-avn-101-potent-small-molecule-for-treatment-of-alzheimer%E2%80%99s-disease-and-anxiety/ (accessed May 14, 2014).
194. News and Events (Avineuro Pharmaceuticals, Inc. reports positive phase I clinical trial results on AVN-322, potent small molecule for the treatment of Alzheimer's disease). March 1st, 2010. http://www.avineuro.com/avineuro-pharmaceuticals-inc-reports-positive-phase-i-clinical-trial-results-on-avn-322-potent-small-molecule-for-treatment-of-alzheimer%E2%80%99s-disease/ (accessed May 14, 2014).
195. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase IIb Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia. July 15, 2013. http://www.avineuro.com/category/news/ (accessed May 14, 2014).
196. Studies found in clinical trials for PF-05212377: http://clinicaltrials.gov/ct2/results?term=PF-05212377+&Search=Search (accessed May 14, 2014).
197. Studies found in clinical trials for Lu AE58054: http://clinicaltrials.gov/ct2/results?term=Lu-AE58054+&Search=Search (accessed May 14, 2014).
198. Lundbeck's Lu AE58054 Meets Primary Endpoint in Large Placebo-Controlled Clinical Proof of Concept Study in People with Alzheimer's Disease. May 29, 2012. http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=677436 (accessed May 14, 2014).
199. Lundbeck and Otsuka Initiate Phase III Clinical Trials on Lu AE58054 as a New Add-On Treatment for Alzheimer's Disease. October 10, 2013. http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=796082 (accessed May 14, 2014).